Peyronie's disease (PD) is a condition in which fibrotic tissue forms inside the penis, causing painful, curved erections that can make sexual activity difficult or impossible, and which carries a significant psychological burden for those affected¹. It is estimated to affect between 0.3% and 13.1% of men worldwide², although underdiagnosis, delays in seeking medical advice and embarrassment suggest that the true prevalence is higher³.
The lack of visibility of this condition, often kept quiet out of shame or social stigma, remains an obstacle to early detection. Intervening during the acute phase, when inflammatory activity and the progression of symptoms are at their most intense, may help to limit the extent of scarring and deformity.
Therapeutic areas
A new treatment for Peyronie's disease arrives in Spain
NEW OPTION FOR THE ACUTE PHASE
Against this backdrop, IBSA is making available to healthcare professionals a hyaluronic acid-based solution indicated for the treatment of the acute or active phase of Peyronie's disease. Designed to act on the fibrotic plaques associated with PD, it aims to help preserve function and patients' quality of life.
AN EVENT TO BRING INNOVATION TO THE CLINIC
To mark this launch, on Friday 6 November IBSA Iberia held an event in Madrid for healthcare professionals, attended by more than 60 health care professionals. The aim of the meeting was to review the most relevant aspects of Peyronie's disease and to share clinical experience, preliminary results and practical recommendations from centres of excellence that had already incorporated this solution into their clinical practice.
The programme included presentations on the pathophysiology and clinical impact of PD; international guidelines and treatment recommendations; the role of ultrasound in diagnosis and treatment; the challenges of managing the acute phase within the public healthcare system; and the scientific evidence for the product. The event closed with a round table on initial clinical experience and the keys to implementation.
OUR COMMITMENT TO INTIMATE HEALTH
This new solution forms part of IBSA's urogynaecology area, in which the company puts its Caring Innovation philosophy into practice: addressing intimate health with scientific excellence, sensitivity and respect for the person as a whole.
In uro-gynaecology, IBSA embodies its commitment to Caring Innovation by addressing intimate health concerns with scientific excellence, sensitivity, and respect for the whole person. We believe everyone should have the chance to feel fully alive - in their body, their emotions, and their intimacy. For us, feeling should not be a luxury, but a right that belongs to all.
THE IBSA IBERIA PORTFOLIO CONTINUES TO GROW
This launch represents a strategic step for us, strengthening our position in the field of urogynaecology and consolidating our expertise in hyaluronic acid-based technologies, already present in other therapeutic areas of the company, such as aesthetic and osteoarticular medicine.
1 National Health Service. (2024). Peyronie’s disease.
2 Al-Thakafi, S., & Al-Hathal, N. (2016). Translational Andrology and Urology.
3 British Dupuytren’s Society. (2014). Peyronie’s treatments.